×
About 536,874 results
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: U...
https://doi.org/10.1001/jama.2018.14741
JAMA , Curry SJ et. al.

Oct 25th, 2018 - Intimate partner violence (IPV) and abuse of older or vulnerable adults are common in the United States but often remain undetected. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including development of mental health conditions such as depression, posttraumatic stress disorder, anxiety disorders, substan...

IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.
https://doi.org/10.1056/NEJMoa1703768
The New England Journal of Medicine; Vuong LN, Dang VQ et. al.

Jan 10th, 2018 - Among women who are undergoing in vitro fertilization (IVF), the transfer of frozen embryos has been shown to result in a higher rate of live birth than the transfer of fresh embryos in those with infertility associated with the polycystic ovary syndrome. It is not known whether frozen-embryo transfer results in similar benefit in women with infertility that is not associated with the polycysti...

History of breast feeding and risk of incident endometriosis: prospective cohort study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574033
BMJ (Clinical Research Ed.); Farland LV, Eliassen AH et. al.

Aug 30th, 2017 - Objective To investigate the association between lifetime breast feeding, exclusive breast feeding, postpartum amenorrhea, and incidence of endometriosis among parous women.Design Prospective cohort study.Setting Nurses' Health Study II, 1989-2011.Participants 72 394women who reported having one or more pregnancies that lasted at least six months, 3296 of whom had laparoscopically confirmed end...

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
https://doi.org/10.1056/NEJMoa1706450
The New England Journal of Medicine; Robson M, Im SA et. al.

Jun 5th, 2017 - Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (...

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
https://doi.org/10.1056/NEJMoa1612645
The New England Journal of Medicine; Masuda N, Lee SJ et. al.

May 31st, 2017 - Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracyc...

Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women
https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32738
International Journal of Cancer; Carolyn E. Eberle et al

Dec 4th, 2019 - Many hair products contain endocrine‐disrupting compounds and carcinogens potentially relevant to breast cancer. Products used predominately by black women may contain more hormonally‐active compounds. In a national prospective cohort study, we examined the association between hair dye and chemical relaxer/straightener use and breast cancer risk by ethnicity.

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...

Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines
https://annals.org/aim/fullarticle/2756145/breast-cancer-screening-diagnosis-synopsis-european-breast-guidelines
Annals of Internal Medicine; Holger J. Schünemann, et al

Nov 30th, 2019 - This synopsis of the European Breast Guidelines provides recommendations regarding organized screening programs for women aged 40 to 75 years who are at average risk. The recommendations address digital mammography screening and the addition of hand-held ultrasonography, automated breast ultrasonography, or magnetic resonance imaging compared with mammography alone. The recommendations also dis...

Quantitative Blood Loss in Obstetric Hemorrhage - ACOG COMMITTEE OPINION, Number 794
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Quantitative_Blood_Loss_in_Obstetric_Hemorrhage_.40.aspx
Obstetrics & Gynecology;

Nov 30th, 2019 - Postpartum hemorrhage causes approximately 11% of maternal deaths in the United States and is the leading cause of death that occurs on the day of birth. Importantly, 54–93% of maternal deaths due to obstetric hemorrhage may be preventable. Studies that have evaluated factors associated with identification and treatment of postpartum hemorrhage have found that imprecise health care provider est...

Pelvic Organ Prolapse ACOG Practice Bulletin, Number 214
https://journals.lww.com/greenjournal/Abstract/2019/11000/Pelvic_Organ_Prolapse__ACOG_Practice_Bulletin,.44.aspx
Obstetrics & Gynecology;

Nov 29th, 2019 - Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect quality of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP sympto...

Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
https://www.nejm.org/doi/10.1056/NEJMoa1903986
NEJM Bakker MF, et al

Nov 27th, 2019 - Extremely dense breast tissue is a risk factor for breast cancer and limits the detection of cancer with mammography. Data are needed on the use of supplemental magnetic resonance imaging (MRI) to improve early detection and reduce interval breast cancers in such patients.

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer
https://jamanetwork.com/journals/jamaoncology/article-abstract/2756224
JAMA Oncology; Mayadev JS, et al

Nov 26th, 2019 - Is immunotherapy after chemoradiotherapy in node-positive cervical cancer tolerable?

Depression in Children and Adolescents: Evaluation and Treatment
https://www.aafp.org/afp/2019/1115/p609.html
American Family Physician; Selph SS et al

Nov 16th, 2019 - he prevalence of major unipolar depression in children and adolescents is increasing in the United States. In 2016, approximately 5% of 12-year-olds and 17% of 17-year-olds reported experiencing a major depressive episode in the previous 12 months. Screening for depression in adolescents 12 years and older should be conducted annually using a validated instrument, such as the Patient Health Que...

Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer
https://jamanetwork.com/journals/jamaoncology/article-abstract/2755638
JAMA Oncology; Mukama T, et al

Nov 13th, 2019 - At what age should women with differing family histories of breast cancer start screening?

Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
https://ascopost.com/news/november-2019/is-there-a-difference-in-breast-cancer-recurrence-rates-after-surgery-with-regional-vs-general-anesthesia/
ASCO Post; Stenger M

Nov 11th, 2019 - In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference in persistent incisional pain between approaches.

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753979
JAMA Network Open; Covelli A, et al

Nov 5th, 2019 - What do clinicians perceive as barriers to engaging in fertility preservation discussions with young women with cancer?

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
https://ascopubs.org/doi/abs/10.1200/JCO.19.00693
Journal of Clinical Oncology; Sharma, P. et. al.

Oct 27th, 2019 - PURPOSE To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS Four hundred twenty-five centrally determined patient cases with TNBC from ...

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials
https://jnnp.bmj.com/content/early/2019/08/29/jnnp-2019-320912
Journal of Neurology, Neurosurgery, & Psychiatry; Bai. S., et al

Oct 27th, 2019 - Objectives To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included ...

Asthma in Adults
https://www.sciencedirect.com/science/article/abs/pii/S0025712519300896?via%3Dihub
Medical Clinics of North America; Nanda A, et al

Oct 27th, 2019 - Asthma affects approximately 300 million people worldwide and approximately 7.5% of adults in the United States. Among adults, asthma results in about 10.5 million physician office visits per year and affects approximately 8.7% of blacks, 7.6% of whites, and 5.8% of Hispanics. Asthma is characterized by inflammation of airways, variable airflow obstruction, and bronchial hyperresponsiveness.3 I...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy
https://ascopost.com/news/october-2019/breast-cancer-gene-expression-signature-may-help-to-predict-recurrence-postradiotherapy/

Oct 13th, 2019 - Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of follow-up needed. These findings were presented by Speers et al at ASCO Breakthrough: A Global Summit fo...

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1712

Oct 9th, 2019 - A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that direct costs for metastatic breast cancer (MBC) patients increase dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology (N...

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Cervical Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq

Oct 4th, 2019 - Based on solid evidence, regular screening of appropriate women for cervical cancer with the Pap test reduces mortality from cervical cancer. The benefits of screening women younger than 21 years are small because of the low prevalence of lesions that will progress to invasive cancer. Screening is not beneficial in women older than 65 years if they have had a recent history of negative test res...

Breast Cancer Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

Oct 3rd, 2019 - Breast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 62,930 cases of in situ disease and 268,600 cases of invasive disease in 2019.[1] Thus, fewer than one of six women diagnosed with breast cancer die of the disease. By comparison, it is estimated that about 66,020 American women will die of lung cancer in 2019. Men account for 1% of breast cancer cases and bre...

American Cancer Society Recommendations for the Early Detection of Breast Cancer
https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

Oct 2nd, 2019 - Finding breast cancer early and getting state-of-the-art cancer treatment are the most important strategies to prevent deaths from breast cancer. Breast cancer that’s found early, when it’s small and has not spread, is easier to treat successfully. Getting regular screening tests is the most reliable way to find breast cancer early. The American Cancer Society has screening guidelines for women...

Medical education needs to stop burning out students — now
https://www.statnews.com/2019/08/29/medical-education-stop-burning-out-students/

Sep 28th, 2019 - Students’ time in medical school should help them grow and become insightful, caring doctors. Instead, medical education is somehow turning smart, gifted, enthusiastic applicants into exhausted and unhappy students who become interns, residents, and physicians at increased risk of depression and burnout.

Over-the-Counter Access to Hormonal Contraception: ACOG Committee Opinion Summary, Number 788
https://journals.lww.com/greenjournal/Fulltext/2019/10000/Over_the_Counter_Access_to_Hormonal_Contraception_.41.aspx
Obstetrics & Gynecology;

Sep 24th, 2019 - ABSTRACT: Barriers to access are one reason for inconsistent or nonuse of contraception. The requirement for a prescription can be an obstacle for some contraceptive users. Several studies have demonstrated that women are capable of using self-screening tools to determine their eligibility for hormonal contraceptive use. Pelvic and breast examinations, cervical cancer screening, and sexually tr...

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

Human versus machine in medicine: can scientific literature answer the question?
https://www.sciencedirect.com/science/article/pii/S2589750019301244?via%3Dihub
The Lancet Digital Health;

Sep 23rd, 2019 - In The Lancet Digital Health, Xiaoxuan Liu and colleagues1 present a systematic review and meta-analysis in an attempt to answer the question of whether deep learning is better than human health-care professionals across all imaging domains of medicine. Despite the plethora of headlines proclaiming how the latest artificial intelligence (AI) has outperformed a human physician, the authors found...

Overall Mortality After Diagnosis of Breast Cancer in Men vs Women
https://jamanetwork.com/journals/jamaoncology/article-abstract/2751525
JAMA Oncology; Wang, F. et. al.

Sep 18th, 2019 - Question To what extent are clinical characteristics and treatment patterns associated with the survival difference between male and female patients with breast cancer? Findings In this large cohort study of 16 025 male and 1 800 708 female patients with breast cancer in the United States, the male patients had 19% higher fully adjusted overall mortality compared with their female counterp...

Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes
https://pubs.rsna.org/doi/10.1148/radiol.2019190971
Radiology

Sep 16th, 2019 - Background Male breast cancer incidence is rising. There may be a potential role in selective screening in men at elevated risk for breast cancer, but the effectiveness of such screening remains unexplored. Purpose To evaluate patterns of male breast imaging utilization, to determine high-risk screening outcomes, and to delineate risk factors associated with cancer diagnosis. Materials ...

Urinary Incontinence in Women: Evaluation and Management
https://www.aafp.org/afp/2019/0915/p339.html
American Family Physician;

Sep 14th, 2019 - Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization ...

Interventions to Prevent Perinatal Depression: Recommendation Statement
https://www.aafp.org/afp/2019/0915/od1.html
American Family Physician;

Sep 14th, 2019 - The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer

Sep 12th, 2019 - The U.S. Food and Drug Administration (FDA) is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs. We have approved new warnings about this risk to the prescribing information and Patient Package Insert for the entire class of these cyclin-dependent kin...

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial
https://annals.org/aim/article-abstract/2749725/menopausal-estrogen-alone-therapy-health-outcomes-women-without-bilateral-oophorectomy
Annals of Internal Medicine;

Sep 9th, 2019 - Background: Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown. Objective: To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups. Design: Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT...

Dense Breasts: Answers to Commonly Asked Questions
https://www.cancer.gov/types/breast/breast-changes/dense-breasts

Sep 6th, 2019 - Mammograms detect breast density, breast cancer, and breast changes that are not cancer (benign breast changes). Breast density describes the amount of glandular and fibrous tissue, as compared to fatty tissue. Learn what factors are associated with breast density and about other risk factors for breast cancer

Discover More About Core Needle Biopsy | Susan G. Komen®
https://ww5.komen.org/BreastCancer/CoreNeedleBiopsy.html

Sep 5th, 2019 - If you have a lump or abnormal mammogram, you may need a core needle biopsy to diagnose, or rule out breast cancer. Learn more about the procedure at Susan G. Komen.

Trial of SAGE-217 in Patients with Major Depressive Disorder
https://www.nejm.org/doi/full/10.1056/NEJMoa1815981
The New England Journal of Medicine; Gunduz-Bruce, H. et. al.

Sep 4th, 2019 - Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.

ASCO Guidelines- Breast Cancer
https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer

Sep 1st, 2019 - All available guidelines for this clinical area are available under the "Select a Guideline" heading. To access a specific guideline, simply click on the title. You may also use the integrated search bar to find guidelines that match your search term. Simply start typing in the search field, and the list of guidelines will filter automatically to display relevant results.

Male Breast Cancer: Developing Drugs for Treatment Guidance for Industry
https://www.fda.gov/media/130061/download

Aug 25th, 2019 - This guidance provides recommendations to sponsors regarding the development and labeling of cancer drugs, including biological products, regulated by CDER and CBER for the treatment of male patients with breast cancer.

Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation
https://ascopubs.org/doi/abs/10.1200/JCO.18.02366
Jimenez, R. et. al.

Aug 25th, 2019 - PURPOSE To evaluate the safety and efficacy of proton beam radiation therapy (RT) for patients with breast cancer who require regional nodal irradiation. METHODS Patients with nonmetastatic breast cancer who required postoperative RT to the breast/chest wall and regional lymphatics and who were considered suboptimal candidates for conventional RT were eligible. The primary end point was th...

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling a...

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1641

Aug 19th, 2019 - Physicians should attempt to maintain full doses of chemotherapy, especially early in the treatment course, for intermediate or high risk breast cancer patients, according to new research published in the August 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network. The study, which looked at the impact of dose reduction with the adjuvant (post-surgery) chemotherapy combinat...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population, BRCA1/2 mutations occur i...

Fulvestrant - National Cancer Institute
https://www.cancer.gov/about-cancer/treatment/drugs/fulvestrant

Aug 14th, 2019 - This page contains brief information about fulvestrant and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

Hirsutism in Women
https://www.aafp.org/afp/2019/0801/p168.html

Jul 31st, 2019 - Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumor...

Pulse waves measured at the wrist uncover often-missed artery changes in menopausal women
https://newsroom.heart.org/news/pulse-waves-measured-at-the-wrist-uncover-often-missed-artery-changes-in-menopausal-women

Jul 28th, 2019 - Measuring a menopausal woman’s pulse wave at her wrist can detect circulatory system changes that aren’t evident with blood pressure readings. Menopause’s effect on these radial pulse wave harmonics can help explain why women in menopause are at heightened cardiovascular disease risk.

Adnexal Torsion in Adolescents
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Adnexal-Torsion-in-Adolescents
Adnexal Torsion in Adolescents

Jul 24th, 2019 - Adnexal torsion is the fifth most common gynecologic emergency. The most common ovarian pathologies found in adolescents with adnexal torsion are benign functional ovarian cysts and benign teratomas. Torsion of malignant ovarian masses in this population is rare. In contrast to adnexal torsion in adults, adnexal torsion in pediatric and adolescent females involves an ovary without an associated...

WHO recommends dolutegravir as preferred HIV treatment option in all populations
https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations

Jul 21st, 2019 - Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause co...

Persistent Organic Pollutants and Breast Cancer: A Systematic Review and Critical Appraisal of the Literature
https://www.mdpi.com/2072-6694/11/8/1063
Cancers Ennour-Idrissi, K. et. al.

Jul 3rd, 2019 - Persistent organic pollutants (POPs) bioaccumulate in the food chain and have been detected in human blood and adipose tissue. Experimental studies demonstrated that POPs can cause and promote growth of breast cancer. However, inconsistent results from epidemiological studies do not support a causal relationship between POPs and breast cancer in women. To identify individual POPs that are repea...

Pfizer Receives U.S. Fda Approval For Its Oncology Biosimilar, Zirabev™ (Bevacizumab-bvzr)
https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr

Jun 26th, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic ren...

ASCO 2019 Report — Breast Cancer
https://www.jwatch.org/na49326/2019/06/19/asco-2019-report-breast-cancer
Gradishar, W. et. al.

Jun 18th, 2019 - At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Editor-in-Chief William J. Gradishar, MD, reviews the key presentations on new breast cancer therapie...

Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP
https://www.aafp.org/afp/2019/0615/od2.html
American Family Physician;

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomized controlled trials and observational studies from January 1, 2003, to August 15, 2017. It is an update to a previous systematic review published ...

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
https://www.amgen.com/media/news-releases/2019/06/fda-approves-amgen-and-allergans-kanjinti-trastuzumabanns-a-biosimilar-to-herceptin-trastuzumab/

Jun 12th, 2019 - Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarc...

Testosterone - Lab Test
https://labtestsonline.org/tests/testosterone

Jun 4th, 2019 - Why Get Tested? To detect an abnormal testosterone level in males and females; in males, to help diagnose the cause of erectile dysfunction or the inability of your partner to get pregnant (infertility); in females, to help diagnose the cause of masculine physical features (virilization), infertility, or polycystic ovary syndrome (PCOS); in children, to help determine the cause of genitals tha...

Antidepressants plus benzodiazepines for adults with major depression
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001026.pub2/full
The Cochrane Database of Systematic Reviews; Ogawa, Y. et. al.

Jun 2nd, 2019 - Background Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective and not any more harmful than antidepressants alone. It has been suggested that benzodiazepines may lose their efficacy with long‐te...

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1904819?query=recirc_curatedRelated_article
The New England Journal of Medicine; Sparano, J. et. al.

Jun 1st, 2019 - The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known. METHODS We performed a prospective trial involving 9427 women with hormone-recept...

Breast Cancer Risk Factors - breastcancer.org
https://www.breastcancer.org/risk/factors

May 31st, 2019 - Every woman wants to know what she can do to lower her risk of breast cancer. Some of the factors associated with breast cancer -- being a woman, your age, and your genetics, for example -- can't be changed. Other factors -- being overweight, lack of exercise, smoking cigarettes, and eating unhealthy food -- can be changed by making choices. By choosing the healthiest lifestyle options possible...

Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
https://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-receive-u-s-fda-approv.aspx

May 27th, 2019 - Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR® (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. VRAYLAR is also approved in the U.S. to treat manic or mixed episodes associated with ...

Triple negative breast cancer
https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html

May 25th, 2019 - Learn all about triple negative breast cancer and who is likely to get TNBC. Also, discover treatment options

Management of Acute Obstructive Uterovaginal Anomalies
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Management-of-Acute-Obstructive-Uterovaginal-Anomalies

May 22nd, 2019 - ABSTRACT: Obstructive uterovaginal anomalies may present after puberty with amenorrhea, dysmenorrhea, pelvic pain, recurrent vaginal discharge, or infertility. The evaluation of a patient with a suspected obstructive reproductive anomaly should include a detailed medical history, physical examination, and imaging. The genital examination is critical to differentiate a patient with an imperforat...

Diagnosis and Management of Hymenal Variants
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Diagnosis-and-Management-of-Hymenal-Variants

May 22nd, 2019 - ABSTRACT: At puberty, a patient with an imperforate hymen typically presents with a vaginal bulge of thin hymenal tissue with a dark or bluish hue caused by the hematocolpos behind it. Other findings that may be present include an abdominal mass, urinary retention, dysuria, constipation, and dyschezia. On evaluation, the goal is to differentiate an imperforate hymen from other obstructing anato...

Infertility Workup for the Women’s Health Specialist
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Infertility-Workup-for-the-Womens-Health-Specialist

May 22nd, 2019 - ABSTRACT: Infertility, defined as failure to achieve pregnancy within 12 months of unprotected intercourse or therapeutic donor insemination in women younger than 35 years or within 6 months in women older than 35 years, affects up to 15% of couples. An infertility evaluation may be offered to any patient who by definition has infertility or is at high risk of infertility. Women older than 35 y...

Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2733171
JAMA Network Open; Hsiang, E. et. al.

May 9th, 2019 - Question Are breast and colorectal cancer screening rates associated with the time of day a patient visits the primary care clinician? Findings In this quality improvement study analysis of 33 primary care practices including 19 254 patients eligible for breast cancer screening and 33 468 patients eligible for colorectal cancer screening, both clinician ordering and patient completion of c...

FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need
https://www.cytodyn.com/media/press-releases/detail/328/fda-grants-cytodyn-fast-track-designation-for-leronlimab

May 6th, 2019 - CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients...

FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
https://www.gene.com/media/press-releases/14785/2019-05-03/fda-approves-genentechs-kadcyla-for-adju

May 2nd, 2019 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla® (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women with ovarian cancer. The recommendations focus on pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurre...

Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004317.pub5/full
The Cochrane Database of Systematic Reviews; Mack, N. et. al.

Apr 22nd, 2019 - Worldwide, hormonal contraceptives are among the most popular reversible contraceptives. Despite high perfect‐use effectiveness rates, typical‐use effectiveness rates for shorter‐term methods such as oral and injectable contraceptives are much lower. In large part, this disparity reflects difficulties in ongoing adherence to the contraceptive regimen and low continuation rates. Correct use of c...

Antioxidant; Camellia sinensis; Free radical; Green tea; Matcha
http://www.cqaimh.org/pdf/tool_phq9.pdf

Apr 18th, 2019 - The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians
https://annals.org/aim/fullarticle/2730520/screening-breast-cancer-average-risk-women-guidance-statement-from-american

Apr 15th, 2019 - The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include.

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
https://wwwext.amgen.com/media/news-releases/2019/04/fda-approves-evenity-romosozumabaqqg-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture/

Apr 8th, 2019 - Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (...

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer

Apr 3rd, 2019 - Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Th...

Direct-to-consumer genetic testing
https://www.ama-assn.org/delivering-care/precision-medicine/direct-consumer-genetic-testing

Apr 2nd, 2019 - Types of DTC genetic tests A broad range of genetic test types are offered DTC, including: Carrier testing for diseases such as cystic fibrosis and hemochromatosis Pharmacogenomic testing Testing for predisposition to complex diseases such as hereditary cancers, cardiovascular disease and depression Whole exome or genome sequencing Testing to determine ancestry

The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy
https://www.abstractsonline.com/pp8/
Mudgway, R. et. al.

Apr 2nd, 2019 - Objective: While prior studies evaluating the survival benefit from primary site surgery in stage IV breast cancer patients have provided mixed results, it has been well documented that anti-human epidermal growth factor receptor (HER) therapy for metastatic HER2 positive(+) disease improves outcomes. We sought to examine the impact of primary tumor resection on survival in HER2+ stage IV breas...

Surgery associated with increased survival for patients with HER2+ stage 4 breast cancer
https://www.eurekalert.org/pub_releases/2019-04/aafc-saw032519.php

Apr 1st, 2019 - Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. Between 20 and 30 percent of all newly diagnosed stage 4 breast cancer cases are HER2+, explained the study's lead author, Ross Mudgway, a medical stud...

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30029-4/fulltext
The Lancet Oncology; Moore, K. et. al.

Mar 31st, 2019 - Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5–9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation
https://www.ncbi.nlm.nih.gov/pubmed/30925795
Biomedicines Jones L, et al

Mar 27th, 2019 - The gut microbiota is extremely important for the health of the host across its lifespan.Recent studies have elucidated connections between the gut microbiota and neurological diseaseand disorders such as depression, anxiety, Alzheimer's disease (AD), autism, and a host of otherbrain illnesses. Dysbiosis of the normal gut flora can have negative consequences for humans,especially throughout key...

Center for Male Contraceptive Research & Development
https://www.malecontraception.center/

Mar 25th, 2019 - The Center for Male Contraceptive Research & Development is your official source for information and regular updates on Male Hormonal Contraception

Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients, According to Researchers from Duke University
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1452

Mar 18th, 2019 - New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy. The RS test helps...

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-fda-approval-zulressotm-brexanolone

Mar 18th, 2019 - Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most co...

AAP Updates Vaccine Recommendations for 2019-2020 Flu Season
https://www.aap.org/en-us/about-the-aap/aap-press-room/Pages/AAP-Updates-Vaccine-Recommendations-for-2019-2020-Flu-Season.aspx

Mar 13th, 2019 - The American Academy of Pediatrics (AAP) will advise families to vaccinate their children against influenza next season with either the flu shot or the nasal spray vaccine for the best protection against the virus during the 2019-2020 flu season. The recommendation differs slightly from last year, when AAP cited a preference for the injected vaccine over the nasal spray - except in cases whe...

A Randomized Trial of Prophylactic Antibiotics for Miscarriage Surgery
https://www.nejm.org/doi/full/10.1056/NEJMoa1808817
The New England Journal of Medicine; Lissauer, D. et. al.

Mar 13th, 2019 - BACKGROUND Surgical intervention is needed in some cases of spontaneous abortion to remove retained products of conception. Antibiotic prophylaxis may reduce the risk of pelvic infection, which is an important complication of this surgery, particularly in low-resource countries. METHODS We conducted a double-blind, placebo-controlled, randomized trial investigating whether antibiotic proph...

Challenges, opportunities remain in breast cancer survivorship care
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7Bf35c2c6b-8b01-4ba6-a618-172474f502e0%7D/challenges-opportunities-remain-in-breast-cancer-survivorship-care

Mar 12th, 2019 - Although significant progress has been made in breast cancer care, challenges and opportunities remain in cancer survivorship, according to a presenter at Miami Breast Cancer Conference. “There are a growing number of breast cancer survivors. It is estimated that there will be more than 18 million cancer survivors in the U.S. alone by 2022, of which 22% are expected to be female breast cancer s...

A New Trio of Genes Enters the Risk Assessment Equation in Hereditary Breast Cancer
https://www.onclive.com/conference-coverage/mbcc-2019/a-new-trio-of-genes-enters-the-risk-assessment-equation-in-hereditary-breast-cancer
Euhus, D.

Mar 12th, 2019 - For many years after the commercialization of multigene panel testing for hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2 remained the most commonly identified pathologic variants. Recent studies have found that variants in genes other than BRCA1 or BRCA2 now account for 56% to 71% of pathogenic variants identified among women recently diagnosed with breast cancer. The majority o...

Scalp-cooling devices gaining momentum in US, but more data needed
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B00fb9ce9-a1e8-40fb-a533-de63ffab11ee%7D/scalp-cooling-devices-gaining-momentum-in-us-but-more-data-needed

Mar 12th, 2019 - Significant advances have been made with scalp-cooling devices to reduce hair loss among women with breast cancer, and this has contributed to increased enthusiasm for these devices in the United States, according to a presenter at Miami Breast Cancer Conference

U.S. FDA Approves Pfizer’s Oncology Biosimilar Trazimera™ (Trastuzumab-qyyp), A Biosimilar To Herceptin®1
https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_oncology_biosimilar_trazimera_trastuzumab_qyyp_a_biosimilar_to_herceptin_1

Mar 10th, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab), for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. “This is an important mil...

VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
https://www.marketwatch.com/press-release/fda-grants-genentechs-tecentriq-in-combination-with-abraxane-accelerated-approval-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer-2019-03-08

Mar 7th, 2019 - Genentech, a member of the Roche Group (six:RO)(six:ROG)(otcqx:RHHBY), today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq [®] (atezolizumab) plus chemotherapy (Abraxane [®] [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metasta...

Coffee and caffeine intake and risk of ovarian cancer: a systematic review and meta-analysis
https://ijgc.bmj.com/content/29/3/579
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society; Shafiei F, et al

Mar 4th, 2019 - Results from earlier publications on the association of coffee and caffeine and risk of ovarian cancer are inconsistent.To evaluate the link between coffee, caffeine, caffeinated coffee, and decaffeinated coffee consumption and risk of ovarian cancer.We searched PubMed/Medline, ISI Web of Science, Scopus, and Google Scholar to identify relevant publications up to April 2018. All case–control st...

Osteoporosis (Secondary) - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK470166/
Ganesan, K. et. al.

Mar 1st, 2019 - Osteoporosis is a bone disorder which is characterized by a decrease in bone strength, resulting from reduced bone mineral density, microarchitectural disruption, and skeletal fragility, thereby causing an increased risk of fracture. Secondary osteoporosis, which occurs due to the presence of underlying disease or medications, can also lead to low bone mass, resulting in increased risk of fract...

Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011
https://jnccn.org/view/journals/jnccn/17/3/article-p245.xml
Journal of the National Comprehensive Cancer Network; Dinan, M. et. al.

Feb 28th, 2019 - The introduction of genomic tests such as the Oncotype DX 21-gene recurrence score (RS) assay has allowed the omission of adjuvant chemotherapy for patients with estrogen receptor (ER)–positive, node-negative breast cancer who have a low RS. Most economic models used to examine the impact of RS testing on overall and chemotherapy-related costs have suggested that RS testing is cost-saving or co...

2019 ASCO-SITC Clinical Immuno-Oncology Symposium Program
https://immunosym.org/program

Feb 27th, 2019 - Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on the clinical application of scientific advances in immuno-oncology. At the 2019 Symposium, expert faculty will offer new insights on the application of immunotherapy in lung cancer, genitourinary cancers, melanoma and other skin cancers, breast cancer, and gyne...

Vaccine Storage and Handling
https://www.cdc.gov/vaccines/hcp/admin/storage/index.html

Feb 27th, 2019 - Proper vaccine storage and handling practices play a very important role in protecting individuals and communities from vaccine-preventable diseases.Vaccine quality is the shared responsibility of everyone, from the time vaccine is manufactured until it is administered.

FDA Warns Thermography Should Not Be Used in Place of Mammography to Detect, Diagnose, or Screen for Breast Cancer: FDA Safety Communication
https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm631885.htm?utm_campaign=FDA%20Warns%20Thermography%20Should%20Not%20Be%20for%20Mammography&utm_medium=email&utm_source=Eloqua

Feb 24th, 2019 - The FDA is alerting women, health care providers, and people getting breast cancer screening, that thermography is not an effective alternative to mammography and should not be used in place of mammography for breast cancer screening or diagnosis.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
https://doi.org/10.1056/NEJMoa1814213
Bardia, A. et. al.

Feb 20th, 2019 - Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cl...